All In Biotech

Drug Trial Radar · NCT06783647

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 01(NSCLC)]

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Jun 11, 2025

Primary completion

Dec 24, 2026

Study completion Dec 24, 2026

Sponsor

Lead sponsor
Nanjing Leads Biolabs Co.,LtdIndustry
Sponsor type
Industry
Collaborators
Sun Yat-Sen University Cancer Center
First posted
Jan 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.

Conditions

  • Advanced Solid Tumour

Interventions

  • LBL-024 for InjectionDrug

    intravenous infusion.

  • Docetaxel InjectionDrug

    intravenous infusion.

  • Bevacizumab InjectionDrug

    intravenous infusion.

  • Pemetrexed Disodium for InjectionDrug

    intravenous infusion.

  • Paclitaxel InjectionDrug

    intravenous infusion.

  • Carboplatin InjectionDrug

    intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Chest Hospital,Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital of Guangdong Pharmaceutical University

    Guangzhou, Guangdong, China · Recruiting

  • Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, Henan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Ganzhou People's Hospital

    Ganzhou, Jiangxi, China · Recruiting

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China · Recruiting

  • Liaoning Cancer Hospital and Institute

    Shenyang, Liaoning, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Recruiting

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China · Recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Recruiting

  • Mianyang Central Hospital

    Mianyang, Sichuan, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • Taizhou Hospital of Zhejiang Province

    Taizhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.